Key Publications by Topic

➯ The Journal of Pathology – Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial – August, 2023

➯ JCO Clinical Cancer Information – Multi-Omic Integration of Blood-Based Tumor-Associated Genomic and Lipidomic Profiles Using Machine Learning Models in Metastatic Prostate Cancer – August, 2023

➯ eBioMedicine – BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype – August, 2023

➯ Nature Communications –  The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma – August, 2022

➯ The American Journal of Surgical Pathology – Triple-negative Breast Carcinoma With Apocrine and Histiocytoid features – June, 2023

➯ Frontiers in Oncology –Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients – June, 2023

➯ PLoS ONE – Direct comparison of circulating tumor DNA sequencing assays with targeted large gene panels – May, 2022

➯ Journal of Translational Medicine – Identification of mutation patterns and circulating tumour DNA-derived prognostic markets in advanced breast cancer patients – May, 2022

➯ Frontiers in Oncology – Germline Mutational Landscape in Chinese Patients with Advanced Breast Cancer – April, 2022

➯ Frontiers in Oncology – Urine- and Blood-Based Molecular Profiling of Human Prostate Cancer – March, 2022

➯ Scientific Reports – Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer – March, 2022

➯ The Journal of Urology – Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer – September, 2021

➯ Breast Cancer Research and Treatment – Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China – September, 2021

➯ European Urology – Avelumab combined with stereotactic ablative body radiotherapy (SABR) in metastatic castration-resistant prostate cancer (mCRPC): the phase 2 ICE-PAC clinical trial – September, 2021

➯ Frontiers in Oncology – Circulating Cell-Free DNA-Based Detection of Tumor Suppressor Gene Copy Number Loss and Its Clinical Implication in Metastatic Prostate Cancer – August, 2021

➯  Journal of Cancer Science and Clinical Therapies – Molecular Mechanisms of Resistance to Osimertinib from Liquid Biopsies of Plasma and Pleura Effusion in EGFR Mutant NSCLC Patients – May, 2021

➯ JCO Precision Oncology – Plasma Cell–Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer – April, 2021

➯ Cancer Management and Research – Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing – April, 2021

➯ The Breast – Peripheral cytotoxic T lymphocyte predicts first-line progression free survival in HER2-positive advanced breast cancer – November, 2020

➯ Blood – A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study – November, 2020

➯ European Urology –Combined cell-free DNA and RNA profiling of the androgen receptor: clinical utility of a novel multi-analyte liquid biopsy assay for metastatic prostate cancer – May, 2020

➯ SIUJ – Utilizing Cell-Free Urinary and Plasma Tumor DNA to Predict Pathologic Stage at Radical Cystectomy – May, 2020

➯ Chinese Journal of Cancer Research – Efficacy of platinum in advanced triple-negative breast cancer (TNBC) with germline BRCA mutation determined by next generation sequencing – February, 2020

➯ ASCO 2023 – Urine-based epigenetic profiling for detection of clear cell renal cell carcinoma: A prospective study – June, 2023

➯ Clinical Cancer Research – Genomic complexity predicts resistance to endocrine therapy and CDK4/6 inhibition in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer – January, 2023

➯ The Lancet Gastroenterology – Gemcitabine and Cisplatin Plus Durvalumad With or Without Tremelimumad in Chemotherapy-Naive Patients with Advanced Biliary Tract Cancer: An Open-Label, Single-Centre, Phase 2 Study – March, 2022

➯ BMC Medicine – Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer – March, 2022

➯ eBioMedicine – enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase – October, 2021

➯ eBioMedicine – Clinical and genomic insights into circulating tumor DNA–based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer – April, 2020

➯ Critical Reviews in Oncology/Hematology –  Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC) – January, 2020

➯ Breast Cancer Research – Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer – October, 2019